132 related articles for article (PubMed ID: 9923575)
1. Estimation of the area under the concentration-versus-time curve of carboplatin following irinotecan using a limited sampling model.
Asai G; Ando Y; Saka H; Ando M; Sugiura S; Sakai S; Hasegawa Y; Shimokata K
Eur J Clin Pharmacol; 1998; 54(9-10):725-7. PubMed ID: 9923575
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Calvert's formula for dosage adjustment of carboplatin in Japanese patients with hormone refractory prostate cancer.
Sato E; Yano I; Jiko M; Takahashi K; Motohashi H; Masuda S; Katsura T; Nishiyama H; Segawa T; Ito N; Kamoto T; Ogawa O; Inui K
Biol Pharm Bull; 2006 Jul; 29(7):1441-4. PubMed ID: 16819185
[TBL] [Abstract][Full Text] [Related]
3. Adjustment of creatinine clearance improves accuracy of Calvert's formula for carboplatin dosing.
Ando Y; Minami H; Saka H; Ando M; Sakai S; Shimokata K
Br J Cancer; 1997; 76(8):1067-71. PubMed ID: 9376268
[TBL] [Abstract][Full Text] [Related]
4. Limited sampling models for simultaneous estimation of the pharmacokinetics of irinotecan and its active metabolite SN-38.
Chabot GG
Cancer Chemother Pharmacol; 1995; 36(6):463-72. PubMed ID: 7554037
[TBL] [Abstract][Full Text] [Related]
5. A phase I clinical and pharmacologic study of a carboplatin and irinotecan regimen combined with recombinant human granulocyte-colony stimulating factor in the treatment of patients with advanced nonsmall cell lung carcinoma.
Okamoto H; Nagatomo A; Kunitoh H; Kunikane H; Watanabe K
Cancer; 1998 Jun; 82(11):2166-72. PubMed ID: 9610696
[TBL] [Abstract][Full Text] [Related]
6. [Evaluation of expected AUC of carboplatin (CBDCA) predicted by Chatelut's formula in comparison with Calvert's].
Nakamura T; Onishi Y; Kono T; Maeda T; Wada T; Hatae M
Gan To Kagaku Ryoho; 1997 Mar; 24(5):579-83. PubMed ID: 9087291
[TBL] [Abstract][Full Text] [Related]
7. A limited sampling method for estimation of the etoposide area under the curve.
Strömgren AS; Sørensen BT; Jakobsen P; Jakobsen A
Cancer Chemother Pharmacol; 1993; 32(3):226-30. PubMed ID: 7684658
[TBL] [Abstract][Full Text] [Related]
8. AUC of Calvert's formula in targeted intra-arterial carboplatin chemoradiotherapy for cancer of the oral cavity.
Oya R; Nakamura S; Ikemura K; Takagi S; Mugino H
Br J Cancer; 2004 Jun; 90(11):2062-6. PubMed ID: 15150563
[TBL] [Abstract][Full Text] [Related]
9. Validation of the limited-sampling models for carboplatin AUC in combination chemotherapy with taxanes.
Miyazaki M; Oguri T; Kurata T; Takahashi T; Daga H; Fujitaka K; Isobe T; Nakajima M; Fujiwara Y; Kohno N
Anticancer Res; 2004; 24(3b):1911-4. PubMed ID: 15274375
[TBL] [Abstract][Full Text] [Related]
10. A single-sample assay for the estimation of the area under the free carboplatin plasma concentration versus time curve.
Ghazal-Aswad S; Calvert AH; Newell DR
Cancer Chemother Pharmacol; 1996; 37(5):429-34. PubMed ID: 8599865
[TBL] [Abstract][Full Text] [Related]
11. A limited sampling method for estimation of the carboplatin area under the curve.
Sørensen BT; Strömgren A; Jakobsen P; Jakobsen A
Cancer Chemother Pharmacol; 1993; 31(4):324-7. PubMed ID: 8422698
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic study of carboplatin given on a 5-day intravenous schedule.
Ando Y; Minami H; Saka H; Ando M; Sugiura S; Sakai S; Shimokata K
Jpn J Cancer Res; 1997 May; 88(5):517-21. PubMed ID: 9247610
[TBL] [Abstract][Full Text] [Related]
13. Validation of a limited sampling model for carboplatin in a high-dose chemotherapy combination.
van Warmerdam LJ; Rodenhuis S; van Tellingen O; Maes RA; Beijnen JH
Cancer Chemother Pharmacol; 1994; 35(2):179-81. PubMed ID: 7987998
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of area under the plasma-concentration-versus-time curve-based carboplatin plus standard-dose intravenous etoposide in elderly patients with small-cell lung cancer.
Okamoto H; Watanabe K; Nishiwaki Y; Mori K; Kurita Y; Hayashi I; Masutani M; Nakata K; Tsuchiya S; Isobe H; Saijo N
J Clin Oncol; 1999 Nov; 17(11):3540-5. PubMed ID: 10550152
[TBL] [Abstract][Full Text] [Related]
15. Limited-sampling models for estimation of the carboplatin area under the curve.
Miyazaki M; Fujiwara Y; Takahashi T; Isobe T; Ohune T; Tsuya T; Yamakido M
Anticancer Res; 1997; 17(6D):4571-5. PubMed ID: 9494570
[TBL] [Abstract][Full Text] [Related]
16. Prediction of carboplatin clearance calculated by patient characteristics or 24-hour creatinine clearance: a comparison of the performance of three formulae.
Okamoto H; Nagatomo A; Kunitoh H; Kunikane H; Watanabe K
Cancer Chemother Pharmacol; 1998; 42(4):307-12. PubMed ID: 9744776
[TBL] [Abstract][Full Text] [Related]
17. Limited sampling models for topotecan pharmacokinetics.
van Warmerdam LJ; Verweij J; Rosing H; Schellens JH; Maes RA; Beijnen JH
Ann Oncol; 1994 Mar; 5(3):259-64. PubMed ID: 8186175
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer.
Belani CP; Kearns CM; Zuhowski EG; Erkmen K; Hiponia D; Zacharski D; Engstrom C; Ramanathan RK; Capozzoli MJ; Aisner J; Egorin MJ
J Clin Oncol; 1999 Feb; 17(2):676-84. PubMed ID: 10080614
[TBL] [Abstract][Full Text] [Related]
19. A single 24-hour plasma sample does not predict the carboplatin AUC from carboplatin-paclitaxel combinations or from a high-dose carboplatin-thiotepa-cyclophosphamide regimen.
Panday VR; van Warmerdam LJ; Huizing MT; Rodenhuis S; Schellens JH; Beijnen JH
Cancer Chemother Pharmacol; 1999; 43(5):435-8. PubMed ID: 10100601
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of a formula for individual dosage of nedaplatin based on renal function.
Sato S; Fujiwara H; Oishi T; Shimada M; Machida S; Takei Y; Itamochi H; Suzuki M; Kigawa J
Cancer Chemother Pharmacol; 2012 Mar; 69(3):599-603. PubMed ID: 21918903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
